Braveheart Bio, Inc. (BRVE) stock analysis
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$20.50−0.40 (-1.91%)
Close on Nov 12, 2026Market cap $1.85BP/E –Yield –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
2 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2024 | FY2024 | FY2025 | Trend |
|---|
Cash use needs five years of cash flow figures
Braveheart Bio does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 0 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero–
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income– vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → 17.03
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –
See a number that looks wrong?